Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 1Suspended 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2966Carcinoma, Renal Cell 882Urinary Bladder Neoplasms 711Kidney Neoplasms 457Breast Neoplasms 408Neoplasms 390Neoplasm Metastasis 229Carcinoma, Non-Small-Cell Lung 229Lung Neoplasms 216Ovarian Neoplasms 211Colorectal Neoplasms 204Melanoma 195Carcinoma, Transitional Cell 190Testicular Neoplasms 171Pancreatic Neoplasms 142Sarcoma 129Head and Neck Neoplasms 121Colonic Neoplasms 120Wilms Tumor 119Uterine Cervical Neoplasms 116Stomach Neoplasms 98Neuroblastoma 90Multiple Myeloma 88Lymphoma, Non-Hodgkin 86Esophageal Neoplasms 86Lymphoma 83Carcinoma, Hepatocellular 81Carcinoma, Ovarian Epithelial 80Recurrence 75Squamous Cell Carcinoma of Head and Neck 74

Interventions

radium Ra 223 dichloride 1atezolizumab 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Castrate-Resistant Prostate Cancer × Genitourinary × Clear all
NCT01234025 2023-10-06

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Ionis Pharmaceuticals, Inc.

Phase 1/2 Completed
113 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT04768608 2023-07-17

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Zhejiang University

Phase 1 Completed
3 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Hoffmann-La Roche

Phase 1 Completed
45 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡